GlobeNewswire Clinical StudiesOriginal article
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
Data ReadoutpositiveOlvi-VecPositive
AI Analysis
Summary
Genelux published results of a platinum-relapsed small cell lung cancer patient who achieved superior progression-free survival and tumor reduction following Olvi-Vec-primed immunochemotherapy compared to first-line therapy.
Clinical Trial Data
Primary Endpoint
Met
Patients
1
Outcome Details
Platinum-relapsed SCLC patient achieved 16.7 months progression-free survival with Olvi-Vec and platinum rechallenge, exceeding first-line PFS, with 84.6% target lesion size reduction
Importance:5/10
Sentiment:
0.70
Olvi-VecSCLCplatinum-relapsedimmunochemotherapypublicationcase report
Read the original article
Published by GlobeNewswire Clinical Studies on September 9, 2026 8:01 PM